


Cite this as: Hui-ying WANG, Yu DAI, Jiao-li WANG, Xu-yan YANG, Xin-guo JIANG, 2015. Anti-CD69 monoclonal antibody treatment inhibits airway inflammation in a mouse model of asthma. *Journal of Zhejiang University-Science B (Biomedicine & Biotechnology)*. **16(7):622-631**. [doi:10.1631/jzus.B1400285]

Anti-CD69 monoclonal antibody treatment inhibits airway inflammation in a mouse model of asthma

Key words: Cluster of differentiation 69 (CD69), Eosinophil, Interleukin-5 (IL-5), Asthma

Research Summary

The present study demonstrated the therapeutic effect of anti-CD69 mAb in eliminating established airway inflammation asthmatic mice from the following aspects:



- Eliminate airway eosinophil infiltration
- Inhibit airway mucus production
- Reduce BALF IL-5 level
- Inhibit airway hyper-responsiveness



Innovation points

- **Identification** of a new antibody that could inhibit the established airway inflammation of asthmatic mice
- **Comparison** of the therapeutic efficiency of anti-CD69mAb to DXM, the classic first-line drug for asthma
- **Introduction a potential potential** alternative regimen for the therapy of asthma and its exacerbation.




Figure 4